Related Experiment Video
Updated: Jun 22, 2026
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
[Prognostic factors of stage III endometrial carcinoma]
1Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100025, China.
Objective:
To investigate the prognostic factors of surgery-pathological stage III endometrial cancer.
Method:
The clinical data of 102 patients with stage III endometrial cancer, aged 54.9 (27-79), 71 with endometrioid adenocarcinoma, 31 with non-endometrioid adenocarcinoma, 9 undergoing simple surgical treatment, and 42 receiving radiation, 16 receiving chemotherapy, and 35 receiving chemoradiation after surgery, were analyzed retrospectively. Follow-up was conducted for 56 (3-192) months.
Results:
Cox risk model analysis showed that the risk factors for the prognosis of stage III endometrial cancer were pathological types, method of treatment, vascular thrombosis, and age (all P < 0.05). The average survival time of stage III a endometrial cancer patients purely positive in peritoneal cytology was 74.4 months, significantly longer than that of the patients with serosa and/or annex involvement (53.8 months, P < 0.05).
Conclusion:
The independent prognostic factors of stage III endometrial cancer are pathological type, method of treatment, vascular thrombosis, and age. The patients with, the prognosis of stage III a endometrial cancer simply positive in peritoneal cytology is better than that with serous and/or annex involvement.